MiMedx Group Q4 2022 Earnings Report $9.10 +0.02 (+0.22%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast MiMedx Group EPS ResultsActual EPS-$0.02Consensus EPS -$0.02Beat/MissMet ExpectationsOne Year Ago EPSN/AMiMedx Group Revenue ResultsActual Revenue$74.38 millionExpected Revenue$74.31 millionBeat/MissBeat by +$70.00 thousandYoY Revenue GrowthN/AMiMedx Group Announcement DetailsQuarterQ4 2022Date2/28/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseMDXG Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. MiMedx Group Earnings HeadlinesMiMedx Files Against Patent Infringement Of Surgenexs's Placental Allograft ProductsDecember 18 at 1:28 AM | markets.businessinsider.comMIMEDX Files Patent Infringement Lawsuit Against SurgenexDecember 18 at 1:28 AM | markets.businessinsider.comAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024December 21, 2024 | True Market Insiders (Ad)Craig-Hallum Sticks to Their Buy Rating for MiMedx Group (MDXG)December 11, 2024 | markets.businessinsider.comInstitutional investors own a significant stake of 43% in MiMedx Group, Inc. (NASDAQ:MDXG)December 2, 2024 | finance.yahoo.comNorthland Securities Sticks to Its Buy Rating for MiMedx Group (MDXG)November 27, 2024 | markets.businessinsider.comSee More MiMedx Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MiMedx Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiMedx Group and other key companies, straight to your email. Email Address About MiMedx GroupMiMedx Group (NASDAQ:MDXG) develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.View MiMedx Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
